Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve

BACKGROUND: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the efficacy of anti-LINGO-1 antibodies in acute optic neuritis and relapsing forms of multiple sclerosis, respectively. Across a range of experimental models, LINGO-1 has been found to inhibit neuron an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gresle, Melissa M, Liu, Yaou, Kilpatrick, Trevor J, Kemper, Dennis, Wu, Qi-Zhu, Hu, Bing, Fu, Qing-Ling, So, Kwok-Fai, Sheng, Guoqing, Huang, Guanrong, Pepinsky, Blake, Butzkueven, Helmut, Mi, Sha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433342/
https://www.ncbi.nlm.nih.gov/pubmed/28607723
http://dx.doi.org/10.1177/2055217316641704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433342/
https://www.ncbi.nlm.nih.gov/pubmed/28607723
http://dx.doi.org/10.1177/2055217316641704

Ejemplares similares